The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Cancer drugs and the heart: importance and management
Open accessAbstract
Progress in the detection and treatment of cancer has led to an impressive reduction in both mortality and morbidity. Due to their mechanism of action, however, conventional chemotherapeutics and some of the newer anti-cancer signaling inhibitors carry a substantial risk of cardiovascular side effects that include cardiac dysfunction and heart failure, arterial hypertension, vasospastic and thromboembolic ischaemia, dysrhythmia, and QT prolongation. While some of these side effects are irreversible and cause progressive cardiovascular disease, others induce only temporary dysfunction with no apparent long-term sequelae for the patient. The challenge for the cardiovascular specialist is to balance the need for life-saving cancer treatment with the assessment of risk from cancer drug-associated cardiovascular side effects to prevent long-term damage. This review discusses concepts for timely diagnosis, intervention, and surveillance of cancer patients undergoing treatment, and provides approaches to clinical uncertainties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“This incidence was much higher than that associated with anthracycline treatment alone.(26) One common finding was that the concomitant use of trastuzumab with anthracycline greatly increased the risk of cardiotoxicity.”
ResultBevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Estimates of the cancer incidence and mortality in Europe in 2006
Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., & Boyle, P. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl498 · Cited by 4,036
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Estimates of cancer incidence and mortality in Europe in 2008
Ferlay, J., Parkin, D. M., & Steliarova-Foucher, E. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.014 · Cited by 2,319
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Self-citationO’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Cardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
Lamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1446 · Cited by 1,159
Anthracycline-Induced Cardiomyopathy
Cardinale, D., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., De Giacomi, G., Rubino, M., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.03.095 · Cited by 1,105
Cardinale, D., Sandri, M. T., Colombo, A., Colombo, N., Boeri, M., Lamantia, G., Civelli, M., Peccatori, F., Martinelli, G., Fiorentini, C., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130926.51766.cc · Cited by 955
Lyman, G. H., Khorana, A. A., Falanga, A., Clarke-Pearson, D., Flowers, C., Jahanzeb, M., Kakkar, A., Kuderer, N. M., Levine, M. N., Liebman, H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1283 · Cited by 952
Scappaticci, F. A., Skillings, J. R., Holden, S. N., Gerber, H.-P., Miller, K., Kabbinavar, F., Bergsland, E., Ngai, J., Holmgren, E., Wang, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm086 · Cited by 938
Mechanisms and Models in Heart Failure: The Biomechanical Model and Beyond
Mann, D. L., & Bristow, M. R. (2005) · Circulation · doi:10.1161/circulationaha.104.500546 · Cited by 867
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3852 · Cited by 826
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Force, T., Krause, D. S., & Van Etten, R. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2106 · Cited by 801
Prediction of venous thromboembolism in cancer patients
Ay, C., Dunkler, D., Marosi, C., Chiriac, A.-L., Vormittag, R., Simanek, R., Quehenberger, P., Zielinski, C., & Pabinger, I. (2010) · Blood · doi:10.1182/blood-2010-02-270116 · Cited by 772
Nalluri, S. R., Chu, D., Keresztes, R., Zhu, X., & Wu, S. (2008) · JAMA · doi:10.1001/jama.2008.656 · Cited by 771
Smith, L. A., Cornelius, V. R., Plummer, C. J., Levitt, G., Verrill, M., Canney, P., & Jones, A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-337 · Cited by 753
Ewer, M. S., Vooletich, M. T., Durand, J.-B., Woods, M. L., Davis, J. R., Valero, V., & Lenihan, D. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.300 · Cited by 726
Self-citationPerez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kaufman, P. A., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0868 · Cited by 717
Adverse effects of anticancer agents that target the VEGF pathway
Chen, H. X., & Cleck, J. N. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.94 · Cited by 560
Cardioprotective interventions for cancer patients receiving anthracyclines
van Dalen, E. C., Caron, H. N., Dickinson, H. O., & Kremer, L. C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003917.pub4 · Cited by 553
Wells, S. A., Gosnell, J. E., Gagel, R. F., Moley, J., Pfister, D., Sosa, J. A., Skinner, M., Krebs, A., Vasselli, J., & Schlumberger, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6604 · Cited by 519
Kantarjian, H. M., Hochhaus, A., Saglio, G., De Souza, C., Flinn, I. W., Stenke, L., Goh, Y.-T., Rosti, G., Nakamae, H., Gallagher, N. J., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70201-7 · Cited by 513
Anthracycline Cardiotoxicity: From Bench to Bedside
Gianni, L., Herman, E. H., Lipshultz, S. E., Minotti, G., Sarvazyan, N., & Sawyer, D. B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9401 · Cited by 454
Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries
Ku, D. D., Zaleski, J. K., Liu, S., & Brock, T. A. (1993) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1993.265.2.h586 · Cited by 445
Choueiri, T. K., Schutz, F. A. B., Je, Y., Rosenberg, J. E., & Bellmunt, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2757 · Cited by 434
Eschenhagen, T., Force, T., Ewer, M. S., de Keulenaer, G. W., Suter, T. M., Anker, S. D., Avkiran, M., de Azambuja, E., Balligand, J.-L., Brutsaert, D. L., et al. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq213 · Cited by 413
Self-citationMaitland, M. L., Bakris, G. L., Black, H. R., Chen, H. X., Durand, J.-B., Elliott, W. J., Ivy, S. P., Leier, C. V., Lindenfeld, J., Liu, G., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq091 · Cited by 410
Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
Perez, E. A., Koehler, M., Byrne, J., Preston, A. J., Rappold, E., & Ewer, M. S. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60896-3 · Cited by 388
Self-citationQuintás-Cardama, A., Kantarjian, H., O'Brien, S., Borthakur, G., Bruzzi, J., Munden, R., & Cortes, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0329 · Cited by 388
Wu, S., Chen, J. J., Kudelka, A., Lu, J., & Zhu, X. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70003-2 · Cited by 386
Predictive Value of Cardiac Troponin T in Pediatric Patients at Risk for Myocardial Injury
Lipshultz, S. E., Rifai, N., Sallan, S. E., Lipsitz, S. R., Dalton, V., Sacks, D. B., & Ottlinger, M. E. (1997) · Circulation · doi:10.1161/01.cir.96.8.2641 · Cited by 384
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know
Ewer, M. S., & Ewer, S. M. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.121 · Cited by 373
Self-citationJensen, B. V., Skovsgaard, T., & Nielsen, S. L. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf132 · Cited by 336
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy
Cardinale, D., Sandri, M. T., Martinoni, A., Borghini, E., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Fiorentini, C., & Cipolla, C. M. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf170 · Cited by 313
Zhu, X., Stergiopoulos, K., & Wu, S. (2009) · Acta Oncologica · doi:10.1080/02841860802314720 · Cited by 312
Sawyer, D. B., Zuppinger, C., Miller, T. A., Eppenberger, H. M., & Suter, T. M. (2002) · Circulation · doi:10.1161/01.cir.0000013839.41224.1c · Cited by 292
Self-citationLemmens, K., Doggen, K., & De Keulenaer, G. W. (2007) · Circulation · doi:10.1161/circulationaha.107.690487 · Cited by 286
Different anthracycline derivates for reducing cardiotoxicity in cancer patients
van Dalen, E. C., Michiels, E. M. C., Caron, H. N., & Kremer, L. C. M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005006.pub4 · Cited by 265
Congestive heart failure is a rare event in patients receiving imatinib therapy
Atallah, E., Durand, J.-B., Kantarjian, H., & Cortes, J. (2007) · Blood · doi:10.1182/blood-2007-01-070144 · Cited by 252
Ewer, M. S., Ali, M. K., Mackay, B., Wallace, S., Valdivieso, M., Legha, S. S., Benjamin, R. S., & Haynie, T. P. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.2.112 · Cited by 244
Self-citationProcter, M., Suter, T. M., de Azambuja, E., Dafni, U., van Dooren, V., Muehlbauer, S., Climent, M. A., Rechberger, E., Liu, W. T.-W., Toi, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0463 · Cited by 244
Self-citationIncreased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis
Ranpura, V., Pulipati, B., Chu, D., Zhu, X., & Wu, S. (2010) · American Journal of Hypertension · doi:10.1038/ajh.2010.25 · Cited by 235
TASSANMANGINA, S., CODOREAN, D., METIVIER, M., COSTA, B., HIMBERLIN, C., JOUANNAUD, C., BLAISE, A., ELAERTS, J., & NAZEYROLLAS, P. (2006) · European Journal of Echocardiography · doi:10.1016/j.euje.2005.04.009 · Cited by 213
Di Lorenzo, G., Autorino, R., Bruni, G., Cartenì, G., Ricevuto, E., Tudini, M., Ficorella, C., Romano, C., Aieta, M., Giordano, A., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp025 · Cited by 207
Self-citationFreedman, A. N., Yu, B., Gail, M. H., Costantino, J. P., Graubard, B. I., Vogel, V. G., Anderson, G. L., & McCaskill-Stevens, W. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.0258 · Cited by 191
Elevated B-type natriuretic peptide levels after anthracycline administration
Suzuki, T., Hayashi, D., Yamazaki, T., Mizuno, T., Kanda, Y., Komuro, I., Kurabayashi, M., Yamaoki, K., Mitani, K., Hirai, H., et al. (1998) · American Heart Journal · doi:10.1053/hj.1998.v136.89908 · Cited by 185
Richards, C. J., Je, Y., Schutz, F. A. B., Heng, D. Y. C., Dallabrida, S. M., Moslehi, J. J., & Choueiri, T. K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4309 · Cited by 180
Wassmuth, R., Lentzsch, S., Erdbruegger, U., Schulz-Menger, J., Doerken, B., Dietz, R., & Friedrich, M. G. (2001) · American Heart Journal · doi:10.1067/mhj.2001.115436 · Cited by 160
van Dalen, E. C., van der Pal, H. J. H., Caron, H. N., et al. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005008.pub3 · Cited by 145
Mitani, I., Jain, D., Joska, T. M., Burtness, B. A., & Zaret, B. L. (2003) · Journal of Nuclear Cardiology · doi:10.1067/mnc.2003.7 · Cited by 140
Daugaard, G., Lassen, U., Bie, P., et al. (2004) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2004.03.009 · Cited by 139
Cardiotoxicity with 5‐fluorouracil and capecitabine: more than just vasospastic angina
Stewart, T. V., Pavlakis, N., & Ward, M. (2010) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2009.02144.x · Cited by 132
Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?
de Azambuja, E., Bedard, P. L., Suter, T. M., & Piccart, M. J. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0112-2 · Cited by 108
Self-citationPrinzmetal's angina during 5-fluorouracil chemotherapy
Kleiman, N. S., Lehane, D. E., Geyer, C. E., Pratt, C. M., & Young, J. B. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90465-7 · Cited by 103
Assessment of Anthracycline Cardiomyopathy by Endomyocardial Biopsy
Mackay, B., Ewer, M. S., Carrasco, C. H., & Benjamin, R. S. (1994) · Ultrastructural Pathology · doi:10.3109/01913129409016291 · Cited by 84
Self-citationHypertension as a surrogate marker for the activity of anti-VEGF agents
Mir, O., Ropert, S., Alexandre, J., & Goldwasser, F. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp206 · Cited by 63
Usefulness of Cardiac Resynchronization Therapy in Patients With Adriamycin-Induced Cardiomyopathy
Rickard, J., Kumbhani, D. J., Baranowski, B. J., Martin, D. O., Tang, W. H. W., & Wilkoff, B. L. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.10.024 · Cited by 57
A Historical Perspective of Anthracycline Cardiotoxicity
Ewer, M. S., Hoff, D. D. V., & Benjamin, R. S. (2011) · Heart Failure Clinics · doi:10.1016/j.hfc.2011.03.001 · Cited by 53
Self-citationLongitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer
Altena, R., Hummel, Y. M., Nuver, J., Smit, A. J., Lefrandt, J. D., de Boer, R. A., Voors, A., van den Berg, M. P., de Vries, E. G. E., Boezen, H. M., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr408 · Cited by 50
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citation2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Self-citationZamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Self-citation
Metadata
- Authors
- Suter, T. M., & Ewer, M. S.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-07-12
- Volume
- 34
- Issue
- 15
- Pages
- 1102-1111
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2118466253
- Cited by
- 472
- References
- 66
- FWCI
- 15.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.